Research Home Page
John D. Carter, M.D. is the Director of Clinical Research for the Division of Rheumatology. Dr. Carterís research team includes two study coordinators, Angie Osorio, RN, CCRC, and Nancy Albritton, LPN. He also has the valued assistance of several sub-investigators including Dr. Frank Vasey, Dr. Joanne Valeriano-Marcet, and Dr. Priya Reddy. Dr. Carterís clinical research is supported by both investigator-initiated grants and industry-sponsored trials.
Dr. Carterís primary research interest centers on Chlamydia-induced Reactive Arthritis. Chlamydia trachomatis is the leading sexually-transmitted bacterial infection in the United States. C trachomatis can cause a serious form of arthritis (Reactive Arthritis [ReA]) in some individuals who acquire genital infections with the organisms. Chlamydial infections can also exist in a persistent state. This chlamydial persistence has been linked to not only ReA, but also other potential disease states. It might also play a role in some of the adverse effects that occur with certain treatments for other types of arthritis. Dr. Carterís clinical research is investigating these and other aspects of the relation to chlamydial infections and arthritis. He was also awarded an NIH Grant in 2006 to study a novel treatment for Chlamydia-induced ReA (www.clinicaltrials.gov). He has presented preliminary data from this trial on a national level at the American College of Rheumatology National Convention in November of 2007.
Dr. Carter has also been awarded investigator-initiated grants that have totaled more than $1,000,000 over the past two years alone to study certain aspects of rheumatoid arthritis, gout, and osteoporosis (www.clinicaltrials.gov). Dr. Carter currently has two more grants that are under review at the NIH and the American College of Rheumatology/Research and Education Foundation.
Dr. Carter has also performed important unfunded clinical research that has centered on drug safety. In November 2007, Dr Carter presented this research at a Plenary Session of the American College of Rheumatology National Convention in Boston, MA.
Finally, Dr. Carter is the principal investigator for several industry-sponsored multi-center trials studying novel treatments for rheumatoid arthritis and gout. He is continually adding new industry-sponsored trials to his clinical research.
|Carter JD, Valeriano J, Vasey FB. A Prospective, Randomized 9-Month Comparison of Doxycycline vs. Doxycycline and Rifampin in Undifferentiated Spondyloarthropathy Ė with Special Reference to Chlamydia-Induced Arthritis. Journal of Rheumatology. 31(10):1973-80, 2004.|
|Carter JD, Valeriano J, Vasey FB. Antimicrobials for the Treatment of Chlamydia-Induced Reactive Arthritis. Annals of the Rheumatic Diseases. 64(3):512-3, 2005.|
|Carter, JD, Espinoza LR. The Interplay of Environment and Host Response in Reactive Arthritis: Can We Intervene? Future Rheumatology. 1(6):717-27, 2006.|
|Carter JD, Gerard HC, Hudson AP. Psoriasiform Lesions Induced by TNF Antagonists: A Skin-Deep Medical Conundrum. Annals of the Rheumatic Diseases (in press)|
|Carter JD, Vasey FB, Valeriano J. The Effect of a Low Carbohydrate Diet on Bone Turnover. Osteoporosis International. 17(9):1398-1403, 2006.|
|Carter JD, Patel S, Sultan FL, Thompson ZJ, Hemstreet M, Sterrett A, Carney G, Murphy N, Huang Y, Valeriano J, Vasey FB. The Recognition and Treatment of Vertebral Fractures in Males with Chronic Obstructive Pulmonary Disease. Respiratory Medicine. (in press)|
|Carter JD, Ladhani A, Ricca L, Valeriano J, Vasey FB. A Safety Assessment of the TNF Antagonists During Pregnancy: A Review of the FDA Database. An Evaluation of Predictive Factors. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007. ARTHRITIS RHEUM 2007;Vol.56, No.9:S286. (Accepted as a Presentation at Plenary Session I).|